Sentrx Surgical

KalVista Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet needs. Originally founded as Sentrx Surgical in 2004, the company evolved through a series of name changes to Carbylan Therapeutics before completing a reverse merger with KalVista Pharmaceuticals Ltd. in 2016. The company's primary focus is on oral therapies for hereditary angioedema (HAE) and diabetic macular edema (DME), leveraging its deep expertise in serine protease biology. Its lead candidate, sebetralstat, is an oral plasma kallikrein inhibitor that has successfully completed Phase 3 trials for the on-demand treatment of HAE. Historically, the company also developed hyaluronic acid-based hydrogel technologies for surgical and orthopedic applications, which led to the spin-off of Sentrx Animal Care.